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Abstract 
 Type-D personality is characterized by the stable traits of negative 
affectivity and social inhibition. In recent years, a body of studies has examined 
the relationship between the presence of Type-D personality and prognosis in 
cardiovascular patient populations. The present meta-analysis, investigated 
relationships between Type-D personality and three different outcome 
measures: major adverse cardiac events, quality of life, and biochemical markers 
of disease. A random effects meta-analytic model was utilized to calculate 
omnibus effect sizes for each set of related studies. Tests of homogeneity were 
conducted, and all studies were coded for the presence of potential moderators. 
A total of 14 studies were included in the meta-analysis, and one effect size was 
calculated in the major adverse cardiac event analysis, two were calculated in 
the quality of life analysis and seven effect sizes were calculated for the 
biochemical marker analysis. An association was found between Type-D 
personality and major adverse cardiac events, one measure of quality of life, 
interleukin-6 levels and tumor necrosis factor-alpha soluble receptor levels. No 
association was found with respect to cortisol or tumor necrosis factor-alpha 
levels. All other effect sizes trended towards significance. It is suggested that a 
broader body of research be conducted in this area in order to generalize these 
associations. Research is also warranted to investigate the effects of treatment 
with a focus on alleviating emotional distress on Type-D individuals in order to 
identify options to improve prognosis in this high-risk patient group. 
 
Table of Contents 
 
Capstone Project Body………………………………………………………………………………………………………..1 
 
References…………………………………………………………………………………………………………………………37 
 
Appendix A: SF-36………………………………………………………………………………………………………………43 
 
Appendix B: Minnesota Living with Heart Failure Questionnaire……………………………………….48 
 
Appendix C: Cantril Ladder of Life……………………………………………………………………………………..50 
 
Appendix D: Health Complaints Scale………………………………………………………………………………..51 
 
Appendix E: WHOQOL-BREF………………………………………………………………………………………………54 
 
Appendix F: Coding Manual……………………………………………………………………………………………….61 
 
Appendix G: Coding Form………………………………………………………………………………………………….67 
 
Figure 1: Exclusion Flow Chart…………………………………………………………………………………………..69 
 
Table 1: Summary of Study Information…………………………………………………………………………….70 
 
Table 2: Summary of Statistical Data…………………………………………………………………………………73 
 
Capstone Project Written Summary………………………………………………………………………………….75 
1 
 
Introduction 
     Since the relatively recent proposal of the Type-D (distressed) personality 
construct, there has been an abundance of research investigating the relations 
between Type-D personality and various psychological and somatic symptoms. 
Type-D personality is the combination of two stable personality constructs: 
negative affectivity and social inhibition. Negative affectivity is the tendency to 
consistently experience negative emotions regardless of the time or situation 
whereas social inhibition is the stable tendency to inhibit the expression of these 
emotions, experience high levels of insecurity in social situations and act closed-
off or reserved for fear of disapproval by others (Denollet, 1998; Denollet, Vaes, 
& Brutsaert, 2000). Whereas negative affectivity and social inhibition 
independently have been demonstrated to have detrimental effects on cardiac 
prognosis, it is their interaction as manifest in the Type-D personality that has 
been shown in individual studies to be predictive of major adverse cardiac 
events (MACE) which include death, myocardial infarction, percutaneous 
coronary intervention and coronary artery bypass grafting surgery (Denollet et 
al., 2006).  
Type-D personality has also been demonstrated to be a stable taxonomy in 
acute myocardial infarction patients who were assessed for Type-D personality, 
depression and anxiety at multiple time points over an 18-month period. 
Variability in mood status and disease severity did not have an association with 
Type-D personality diagnosis (Martens, Kupper, Pederson, Aquarius, & Denollet, 
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2007).  Issues concerning the similarities and differences between Type-D and 
depression have also been addressed. However, in further examination by 
Denollet and colleagues of whether Type-D personality and depression are 
different forms of emotional distress, it was found that Type-D personality is not 
due to co-morbid depression as only 25% of their total sample of 340 cardiac 
patients exhibited both depression and Type-D personality whereas the other 
75% were diagnosed with either Type-D personality or depression. This study 
also concluded that Type-D personality cannot be assumed from a diagnosis of 
depression and that the findings support the validity of the two forms of distress 
as separate constructs; depression being a disorder that lacks the trait of social 
inhibition and Type-D being a stable personality construct including both the 
personality traits of negative affectivity and social inhibition (Denollet et al, 
2009). 
The individual constructs which constitute Type-D personality have also been 
assessed individually to determine their relationship with cardiac prognosis. In a 
2006 study, Denollet and colleagues assessed the role which social inhibition 
plays with respect to the role of negative emotions’ effect on cardiac prognosis 
(Denollet et al., 2006). A total of 875 subjects were assessed on separate scales 
of negative affectivity and social inhibition six months post percutaneous 
coronary intervention. It was found that patients with high levels of negative 
affectivity and social inhibition were more likely to experience MACE than 
patients who were only classified as having high levels of negative affectivity. 
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This suggests that it is the interaction between negative affectivity and social 
inhibition, which together constitute Type-D personality, and not merely the 
presence of one trait or the other, which may account for poor cardiac 
prognosis. 
Previous research found links between Type-D personality and multiple 
predictors of poor prognosis in cardiac patients. Type-D is a predictor of clinically 
significant and chronic anxiety in chronic heart failure and percutaneous 
coronary intervention patients at one year follow up (Schiffer, Pederson, Broers, 
Widdershoven, & Denollet, 2008; van Gestel et al., 2007; Spindler, Pederson, 
Serruys, Erdman, & van Domburg, 2007) and elevated anxiety levels in 
implantable cardioverter defibrillator patients (Pederson, van Domburg, Theuns, 
Jordaens, & Wedman 2004). Another risk factor for increased morbidity that has 
been linked to Type-D personality is vital exhaustion (Kop, 1997; Kop, 1999). In a 
sample of 171 patients with ischemic heart disease, patients who were identified 
as having Type-D personality scored higher on assessments of vital exhaustion 
independent of other variables (Pederson & Middel, 2001). Type-D personality 
has also been shown to have a relationship with vital exhaustion in percutaneous 
coronary intervention patients over the course of one year with Type-D patients 
consistently scoring higher on vital exhaustion assessments than non Type-D 
patients (Pederson, Daemen, & van de Sande, 2007).  Both vital exhaustion and 
Type-D personality are independently associated with inadequate heart rate 
recovery, another predictor of morbidity and mortality, in chronic heart failure 
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patients (von Kanel et al, 2009). Epithelial progenitor cells, necessary for the 
repair of damage to the body including vascular damage, are reduced by 54% in 
Type-D chronic heart failure patients as compared to non Type-D patients 
(Craenenbroeck, Denollet, Paelinck, & Conraads, 2009). Type-D personality has 
also been linked with low levels of health related behaviors and reduced levels of 
social support which are associated with a negative impact on cardiac outcomes 
(Williams et al, 2008). Social support sublevels of structural support (social 
networking and frequency of contact) and functional support (received and 
perceived social support) have reliably been connected to cardiac death as well 
as mortality from other causes (Rozanski, Blumenthal, Davidson, Saab, & 
Kubzansky, 2005). In research pertaining to potential disease pathways, it has 
been found that cardiac patients with Type-D personality may experience 
prolonged disruption of the hypothalamic-pituitary-adrenal axis after acute 
coronary events resulting in increased cortisol output during the day (Molloy, 
Perkins-Porras, Strike, & Steptoe, 2008). 
Type-D personality has also been found to have predictive power for non-
cardiac populations as well. A recent review from the Center of Research on 
Psychology in Somatic Diseases in Tilburg, Netherlands detailed the associations 
between Type-D personality and disease in non-cardiac populations.  
Correlations were found between the presence of Type-D personality and poor 
performance as well as increased cognitive complaints following traumatic brain 
injury, increased side effects of and poor adherence to treatment of sleep apnea, 
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poor health related quality of life and increased disease related distress in 
tinnitus patients, poor mental quality of life in diabetic foot syndrome patients, 
increased depression and anxiety in chronic pain patients, greater emotional and 
physical disability in peripheral vestibular patients and among melanoma 
survivors it was associated with subpar health status as well as a more 
prominent negative impact of cancer on the patients’ lives. In the primary care 
setting, patients with Type-D personality have been documented as experiencing 
elevated rates of comorbidity, poor personal evaluations of perceived health 
status and poor physical as well as inadequate psychosocial functioning. In 
studies assessing the prevalence of Type-D personality among patient groups, 
higher prevalence was found in vulvovaginal candidiasis and tinnitus patient 
groups (Mols & Denollet, 2010). 
Quality of Life 
Health-related quality of life encompasses the assessment of three 
different domains: biological functioning, psychological functioning and social 
functioning. Health status, functional status and quality of life are all terms used 
to describe the same essential construct. The broad dimensions that are 
included in assessment of health-related quality of life allow for assessment of 
the degree of impairment of cherished aspects of life that are not considered 
traditional health measurements but may be associated with adverse health 
such as autonomy, ability to work, income and environmental quality. This 
measurement takes into account not only the physiologic measures most often 
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relied upon by physicians but other aspects of life which are impacted by chronic 
disease as well. It is only recently that quality of life has gained attention as a 
means to provide clinicians with a more complete picture of patient health 
beyond purely physiological measures such as cholesterol levels or outcome 
measures such as mortality. Its relevance also extends to examine the effects of 
disease treatments, such as percutaneous coronary intervention and coronary 
artery bypass grafting surgery, for which the primary goals are to improve health 
status as well as quality of life. Health-related quality of life is also a possible 
source of variance that can often be observed between two patients with the 
same degree of illness who experience different disease outcomes (Guyatt, 
Feeny, & Patrick, 1993). Following are examples of studies highlighting quality of 
life outcomes in cardiovascular patients. 
Chronic heart failure is a disease that is increasing in prevalence and 
promotes poor quality of life due to difficulty breathing, chronic fatigue, multiple 
re-hospitalizations and peripheral edema which impair daily activities. An 
additional source of importance for quality of life measures is the expressed 
desire by the majority of a sample of chronic heart failure patients for an 
improvement in quality of life over survival (Staneck, Oates, McGhan, Denofrio, 
& Loh, 2000).  
     The general consensus of chronic heart failure patients is well stated by    
Archana (2002):  
     It is not sufficient, therefore, to offer a patient improved survival and add 
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     years to life unless at the same time treatment also adds life to years…from a  
     patients’ perspective, the  limitations  imposed which adversely affect quality 
     of life and impact upon day-to-day activities at home,  leisure time interests  
     and performance at work are of at least equal importance to the constellation  
     of symptoms and signs that form the basis of the medically oriented approach  
     to health assessment. (p. 1806-1807)  
Chronic heart failure patients have been observed to experience impairments in 
all domains of health related quality of life as measured by the SF-36. The 
physical functioning aspect of quality of life in these patients also has been found 
to be more severely impaired than in other common chronic illnesses (Hobbs et 
al., 2002). Poor health-related quality of life has also been associated with 
adverse outcomes and mortality in chronic heart failure patients (Rodigeuz-
Artalejo et al., 2005) and has been predictive of clinical endpoints which indicate 
that it is a valid measure of health status (Tate et al., 2007). 
 Peripheral artery disease is classified as a chronic illness for which one of 
the main goals of treatment is to improve quality of life. Some studies suggest 
that quality of life in peripheral artery disease patients may generally be poorer 
than that of chronic heart failure patients (Liles, Kallen, Peterson, & Bush, 2006). 
Peripheral artery disease limits daily activities and exerts adverse effects on 
quality of life by impairing walking ability, hindering sleep, decreasing energy, 
causing leg pain and sometimes requiring amputation or other surgical 
interventions. Patients report severe limitations in mobility and feelings of 
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inadequacy, fear, uncertainty and being a burden to family and friends which 
severely impairs physical as well as mental health related quality of life (Nehler, 
McDermott, Treat-Jacobson, Chetter, & Regensteiner, 2003).  In recent years, 
the importance of quality of life on the treatment on peripheral artery disease 
patients has been highlighted, and the need to consider the broader impacts of 
peripheral artery disease beyond clinical symptoms and mortality has been 
emphasized. Subjective measures of quality of life have been correlated to 
functional status and objective measures of disease severity. Low scores on the 
mental health dimension of quality of life can also cause further impairment of 
physical health status. Patients who are asymptomatic or experience mild 
symptoms of disease may not function to the full extent of their capabilities due 
to their subjective perceptions of their health status (Liles et al., 2006). 
 Within the population of myocardial infarction patients, main 
contributors to impaired quality of life, compared to healthy community controls 
four and five years post myocardial infarction, are reported to be the inability to 
work, angina, emotional distress, difficulty sleeping and dyspnea (Brown et al., 
1999; Wiklund, Herlitz, & Hjalmarson, 1988). The degree of impairment in the 
quality of life of myocardial infarction patients has also been associated with 
reduced left ventricular ejection fraction and younger age (Petterson, Kvan, 
Rollag, Stavem, & Reikvam, 2008; Bengtsson, Hagman, & Wedel, 2001). A 
reduced quality of life has also been observed in female as opposed to male 
myocardial infarction patients (Agewall, Berglund, & Henareh, 2003). 
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Additionally, interviews of 2,320 male myocardial infarction patients suggest that 
impairments in mental quality of life, more precisely high levels of stress, social 
isolation, depression, anxiety, hostility and anger, may be associated with 
mortality including sudden cardiac death (Ruberman, Weinblatt, Goldberg, & 
Chaudhary, 1984; Peters, 2001). Percutaneous coronary intervention and 
coronary artery bypass grafting surgery are two revascularization procedures 
which aim to improve quality of life. Both of these procedures have been 
demonstrated to equally improve health related quality of life scores six months 
post-revascularization (Rumsfeld et al., 2003). Additionally, poor physical health 
related quality of life has been demonstrated to be an independent predictor of 
mortality following coronary artery bypass grafting surgery (Rumsfeld et al., 
1999).  
Biochemical Markers 
 Additional indicators of prognosis in cardiovascular disease are pro-
inflammatory cytokines which are substances released by immune cells in 
response to tissue injury or infection. Cytokines provoke an immune response 
drawing white blood cells to the damaged area in order to stimulate tissue 
repair. Two members of the pro-inflammatory cytokine family are tumor 
necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6).  These substances are 
activated in a chemical cascade and necessary for immune activation. All 
produce effects of hyperalgesia via release of prostaglandins, nerve growth 
factor, sympathetic activation and direct activation of peripheral nocioceptors 
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(Watkins & Maier, 2000). Pro-inflammatory cytokines often are up-regulated in 
heart failure patients as they are released by myocardial cells, most notably TNF-
α and its soluble receptors (sTNFR-1 and sTNFR-2), in response to cardiac stress.  
High levels of TNF-α, sTNFR-1, sTNFR-2, and IL-6 have consistently been linked to 
severity of heart failure and cardiac mortality with sTNFR-2 levels being the most 
accurate predictor of cardiac mortality (Murray & Freeman, 2003; Valgimigli et 
al, 2005; Ueland et al, 2005; Deswal et al., 2001). Increased levels of pro-
inflammatory cytokines are also associated with the pathogenesis of both 
atherosclerosis and chronic heart disease (Yudkin, Kumari, Humphries, &  
Mohamed-Ali, 2000). 
 Anti-inflammatory cytokines aid in regulation of the inflammatory 
immune response via cytokine inhibitors and soluble cytokine receptors. Two 
varieties of anti-inflammatory cytokines are interleukin-10 (IL-10) and 
interleukin-1 receptor antagonist (IL-1ra). A very delicate balance of pro- and 
anti-inflammatory cytokines is vital in order to ensure a fully functional and 
healthy immune system. Disruptions to this balance are extremely detrimental 
and often result in excessive inflammation and disease. The mechanism of action 
of IL-1ra is to act as a competitive inhibitor at pro-inflammatory interleukin-1 
receptor sites. IL-10 is considered the most essential anti-inflammatory cytokine 
and works as an inhibitor of activity and production of a wide range of pro-
inflammatory cytokines as well as an inhibitor of specific surface expression 
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molecules which signal an inflammatory response (i.e  MHC II complex 
molecules) (Opal & DePalo, 2000).  
 Cortisol is a glucocorticoid often referred to as a stress hormone released 
in response to sympathetic stimulation via the hypothalamic-pituitary-adrenal 
axis. It has been demonstrated that the hypothalamic-pituitary-adrenal axis is 
stimulated by increases in negative affect resulting in increased cortisol levels 
(Buchanan, al’Absi, & Lovallo, 1999; Sher, 2005). Chronically elevated cortisol has 
a disease promoting effect via its influence on the deposition of abdominal 
adipose tissue which is a predictor of cardiovascular disease (Rimm et al., 1995) 
via its hyperlipidemia and insulin resistant effects (Sher, 2005). In addition, 
cortisol has an inhibitory effect on growth hormone causing growth hormone 
deficiencies which are associated with a greater risk of premature cardiovascular 
disease (Erfuth, Bulow, Asklisson, & Hagmar, 1999; Hew, O’Neal, Kamarudin, 
Alford, & Best, 1998). An important aspect of human circadian rhythm is the 
cortisol awakening response. The general secretory pattern of cortisol is a large 
increase in secretion resulting in peak cortisol levels after awakening followed by 
a decrease in cortisol levels throughout the day ending with the lowest levels at 
night and in the early hours of the morning. This is a pattern of increased levels 
of cortisol by 50-75% release within thirty minutes of awakening (Clow, Thorn, 
Evans, & Hucklebridge, 2004) and has been suggested to be a reliable biological 
marker of adrenocortical activity (Pruessner et al, 1997). Increased levels of the 
cortisol awakening response have been observed in chronically stressed 
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individuals in comparison to unstressed controls (Schulz, Kirschbaum, Prubner, & 
Hellhammer, 1998) whereas increased net output of cortisol throughout the day 
has been correlated with abdominal obesity (Rosmond, Dallman, & Bjorntorp, 
1998).   
Summary and Purpose of Current Study 
In addition to the numerous investigations linking Type-D personality to 
various known risk factors for cardiac morbidity and mortality, there is a 
significant amount of research examining this personality type’s value as a 
prognostic predictor following the diagnosis of heart disease using MACE, quality 
of life, and biochemical marker endpoints. Though much work has been 
conducted in examination of the topic as well as a handful of narrative reviews, 
no meta-analysis has been conducted in this area. The completion of a meta-
analysis demonstrates the size of the relationship of Type-D personality with 
cardiac prognosis following the diagnosis of heart disease using the combined 
quantitative data from multiple studies. The use of data from multiple studies 
results in greater statistical power than in the individual studies and thus 
provides a better overview of the state of the research. Therefore, the objective 
of the current study is to conduct a meta-analytic review of the associations 
between Type-D personality and 1) Major adverse cardiac events 2) Quality of 
Life and 3) Levels of Biochemical Markers. 
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Methods 
Study Search Procedure 
 Two search procedures were utilized in order to obtain studies used in 
the present meta-analysis. First, a keyword search was conducted on the 
PsycINFO and PubMed databases. The searches were limited to publications in 
the English language and primary studies. All publications up to the time of the 
search were eligible. The keyword combinations were Type-D personality + 
heart, Type-D personality + mortality, Type-D personality + cardiac mortality and 
Type-D personality + left ventricular ejection fraction. All titles and abstracts 
were examined and potential candidates for the meta-analysis were collected.  
 Second, an ancestral search was conducted using the Schiffer et al. (2009) 
article as a starting point due to its status as the most recent publication at the 
time the ancestral search was conducted. References of all articles obtained 
during the keyword search were also analyzed for potential studies. Any titles 
pertaining to the current topic of study were identified and their abstracts were 
checked for inclusion into the pool of candidate studies for the meta-analysis. 
Studies were added as they were located by both the principal investigator and 
two Ph.D. level collaborators. 
Inclusion and Exclusion Criteria 
 Candidate studies had to meet specific criteria for inclusion into the 
meta-analysis. Studies must (a) have a sample patient population with a 
diagnosis of chronic heart failure, coronary heart disease, myocardial infarction, 
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acute coronary syndrome, peripheral artery disease or have undergone 
percutaneous coronary intervention, implantable cardioverter defibrillator 
implantation, coronary artery bypass grafting surgery,  heart transplantation 
surgery or be participating in a cardiac rehabilitation program; (b) compare 
subsamples of patients diagnosed as Type-D vs. non Type-D; (c) Type-D must be 
assessed using the DS-14, DS-16, DS-24 or a reliable and valid measure of both 
negative affectivity and social inhibition separately in which high levels of both 
negative affectivity and social inhibition are used to classify Type-D patients; (d) 
the study endpoint must be either major adverse cardiac events (MACE), quality 
of life measures or levels of disease promoting biochemical markers. 
 At the conclusion of the search, there were fifty potential studies relating 
Type-D personality to heart disease. Of those studies, five were excluded 
because they either lacked a non Type-D subsample for comparison or assessed 
only negative affectivity or social inhibition individually. An additional three 
studies were excluded because they used healthy patient samples. Of the 
remaining 42 studies, 18 did not include the selected inclusion outcome 
measures. An additional five studies were excluded due to the use of the same 
patients in multiple studies, and one study was excluded due to a lack of cardiac 
events in either patient group. A final four studies were unable to be used in 
calculations of effect sizes because not enough statistical data were provided to 
calculate an effect size (e.g standard deviations missing). The authors of these 
studies were contacted in an attempt to gather additional data but no reply was 
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received. This left 14 studies in the analysis which were then split into three 
categories based on their endpoints: five studies were analyzed with an endpoint 
of MACE, five studies were analyzed for quality of life and four were analyzed 
with respect to biochemical markers (Figure 1).  
Type-D Measurement in Primary Studies 
The studies included in the analysis most often utilized the Type-D Scale-
14 (DS-14) and the Type-D Scale-16 (DS-16) for the assessment of Type-D 
personality. On these diagnostic tools, patients indicate the extent to which they 
agree with statements concerning negative affectivity and social inhibition levels 
using five point Likert-type scales. A rating of 0 indicates disagreement with the 
statement whereas a rating of 4 indicates agreement. There are eight items to 
assess negative affectivity and eight items to assess social inhibition on the DS-16 
(Denollet et al., 1996) whereas there are seven of each on the DS-14, the 
successor of the DS-16 (Emons, Meijer, & Denollet, 2007). The DS-16 and DS-14 
both demonstrate evidence of internal consistency as measures of Type-D 
personality with α=.89 and .88 for measures of negative affectivity and α=.82 
and .86 for social inhibition respectively (Denollet, 2005; Denollet et al., 1996). 
The cutoff for a classification of Type-D personality is a score of 10 or greater on 
both subscales. A median split using a cardiac population was used to establish 
the cutoff point (Denollet, 2005). The Negative Affectivity subscale highly 
correlates with the Trait Anxiety Scale (r=.81) whereas the Social Inhibition 
subscale highly correlates with the Erdman Inhibition Scale (r=.73) (Denollet, 
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1998). The DS-14 has been assessed using item response theory in both general 
and clinical populations. Item response theory is a method used to assess the 
measurement of variables that cannot be directly observed, referred to as latent 
variables, as well as to assess the precision of cutoff scores used in diagnostic 
tools. The item response theory assessment of the DS-14 supports the use of the 
established cut off points in differentiating between Type-D and non Type-D 
personality in both clinical and non clinical populations (Emons et al., 2007). 
Quality of Life Measurement in Primary Studies 
The SF-36 (Appendix A) is a 36 item self-evaluation of health status 
containing scaled measurements for eight different aspects of health: physical 
functioning, social functioning, role limitation due to physical functioning, role 
limitations due to emotional functioning, mental health, vitality, pain and the 
perception of general health (Kaplan, n.d). This evaluation is not disease-specific 
and assesses a wide range of the dimensions contributing to overall health. The 
scores for each individual dimension are coded and combined to produce an 
overall score of health ranging from 0 (poor health) to 100 (excellent health). 
Cronbach’s α exceeds the standard value of 0.85 in all dimensions except social 
functioning (α=.73). The SF-36 also has adequate levels of test-retest reliability at 
two weeks among each of the eight dimensions, with r-values ranging from .60 
to .80, as well as shows strong evidence of construct validity as the SF-36 is able 
to discriminate between patient groups with anticipated differences in their 
health status (Brazier et al., 1992). 
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 The Minnesota Living with Heart Failure Questionairre (MLWHFQ) is a 
disease-specific assessment of the impact of disease on the quality of life of 
chronic heart failure patients (Appendix B). The evaluation consists of 21 items 
rated on a 6-point Likert-type scale rating the impact of heart failure on social, 
physical, mental and emotional aspects of life. It assesses, overall, the extent to 
which heart failure limits individuals from living their optimal lifestyle. High 
scores indicate poor health status. This measurement has high internal 
consistency with a Cronbach’s α ranging from .92 to .95 among numerous 
studies (Rector, 2005). The Cantril Ladder of Life (Appendix C) is an additional 
quality of life measure in which subjects are presented with a vertical ladder on 
which the numbers 1-10 are presented (Jaarsma, Lesman-Leegte, Cleuren, & 
Lucas, 2005). They subjectively evaluate their lives from 1 (worst possible life) to 
10 (best possible life) (Newman, 2005).  This is a very general instrument that 
can be used in all populations and is often used among heart failure patients. 
The Cantril Ladder of life has a two year test-retest coefficient of .7 (Horley & 
Lavery, 1991). The Cantril Ladder of Life and the MLWHFQ have an overall 
correlation coefficient of .36 (Jaarsma et al., 2005). 
 The Health Complaints Scale (Appendix D) assesses 12 somatic and 12 
cognitive common health complaints (Denollet, 1994). This instrument has been 
found to exhibit high internal consistency with a Cronbach’s α of approximately 
.89 as well as sufficient test-retest reliability at three months with a Pearson’s 
correlation coefficient of approximately .69. The Health Complaints Scale has 
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shown good construct validity as correlated with the disability and well-being 
dimensions of the Heart Patients Psychological Questionnaire (Denollet, 1994).  
 The World Health Organization Quality of Life assessment instrument 
(WHOQOL) (Appendix E) is a 100 item quality of life measure providing a 
culturally sensitive subjective self report measurement of a broad range of 
dimensions of quality of life with respect to their various levels of importance 
(Trompenaars, Masthoff, Van Heck, Hodiamont, & De Vries, 2005; World Health 
Organization, 1997).  It has high levels of internal consistency with Cronbach’s α 
ranging from .73 to .91 among the five sub-domains of physical health, 
psychological health, level of independence, social relationships and 
environment as well as α=.91 for overall quality of life and general health.  The 
WHOQOL has also been shown to exhibit an adequate level of construct validity 
when correlated with multiple related questionnaires such as the Sickness 
Impact Profile, Fatigue Impact Scale, Self-Esteem Scale, Life Orientation Test, 
Social Support Questionnaire, Profile of Moods Scale and the Standard Bipolar 
Five-Factor Markers (De Vries & Van Heckk, 1997). 
Coding of Study Characteristics  
 Each study was coded independently for both study level characteristics 
and effect size level characteristics (Lipsey & Wilson, 2001; Appendix F). The 
clinical variables which were coded were those most consistently reported in the 
primary studies. Common authors and sample sources were included in the 
coding due to the concentrated group of investigators as well as limited 
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geographical area in which Type-D research has been conducted. The recorded 
study level characteristics were: publication year, inclusion of Denollet or 
Pederson as authors, sample source (by hospital or cardiac rehabilitation 
program), specific cardiac diagnosis/treatment/procedure, gender proportion 
(percentage male), mean age, method of patient selection, study design, sample 
size and diagnostic tool used to assess Type-D personality. Also recorded for 
study level characteristics were the proportions of the sample engaging in 
tobacco use, with impaired left ventricular ejection fraction (LVEF), 
hyperlipidemia, hypertension, diabetes, renal impairment, NYHA Class III/IV and 
with Type-D personality. It was also noted whether the baseline characteristics 
significantly differed between the Type-D and non Type-D groups. The study-
level characteristics were examined as a source of possible extrinsic and 
substantive variables in moderator analysis. 
 The recorded effect size level characteristics (Appendix F) were: length of 
time of study, specific outcome construct measured, type of data effect size is 
based on (dichotomous frequencies and proportions indicating the occurrence of 
an event or means and standard deviations), page number on which the effect 
size data was found, better or worse outcome for Type-D group, either all 
dichotomous frequencies and proportions or means and standard deviation 
data, whether Type-D personality was found to be a significant predictor of 
worse outcome using 1) univariate significance testing and 2) multivariate 
significance testing and the confidence rating in effect size computation based 
20 
 
on whether any estimation was necessary for data presented graphically without 
presentation of exact numbers. The confidence in the data was rated on a scale 
of 1-5. A rating of 1 indicated a high level of estimation with minimal statistical 
data. A rating of 2 indicated moderate estimation. For example, this would be 
necessary for studies reporting only multifactor ANOVA statistics as a basis for 
estimation. A confidence rating of 3 required some estimation such as that due 
to unconventional statistics needing to be converted to conventional statistics or 
incomplete conventional statistics. A rating of 4 required only slight estimation 
whereas a confidence rating of 5 required no estimation and effect sizes could 
be calculated directly from the data (Lipsey & Wilson, 2001). The effect size level 
coding provided the data necessary to compute effect sizes and provided a 
source of possible method variables in moderator analysis. 
 All coding was completed independently by two individual coders: the 
primary investigator of this study and an individual with a master’s degree in 
cardiac rehabilitation/exercise physiology. A coding book (Appendix F) and 
coding sheets (Appendix G) were developed by the primary investigator and the 
second coder was provided with extensive training with the well-defined coding 
book (Appendix F).  There was agreement on 100% of the study level 
characteristics and 98.6% of the effect size level characteristics for studies 
included in the MACE analysis. For the studies included in the quality of life 
analysis there was 100% agreement on the study level characteristics and 99.4% 
agreement on the effect size level characteristics. There was 100% agreement on 
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both study level and effect size level characteristics for studies included in the 
biochemical markers analysis. In cases of disagreement a decision was made 
following the conference of the raters. 
Effect Size Computation 
 Effect sizes were computed and presented as either odds ratios or 
Hedge’s d. Effect sizes were reported as odds ratios when individual effect sizes 
were gathered from dichotomous frequencies and proportions and were 
reported in the terms of Hedge’s d when the individual effect size data was 
derived from means and standard deviations. In analyses that combined effects 
from multiple studies, effect sizes were weighted by their inverse variance. All 
effect sizes were computed using Comprehensive Meta-Analysis Software 
(Biostat, 2002). 
 For the MACE analysis, only one overall effect size was calculated. There 
were two effect sizes calculated in the quality of life analysis: one using the 
combined effects from studies with continuous data as well as one computed 
from studies with dichotomous data. In the biochemical markers analysis 
multiple effect sizes were calculated. First, effect sizes were calculated 
individually for each of the inflammatory cytokines IL-6 and TNF-α, as well as 
TNF-α soluble receptors sTNFR-1 and sTNFR-2. An effect size was then calculated 
for TNF-α combined with sTNFR-1 and sTNFR-2. These were then combined 
along with IL-6 to obtain an overall inflammatory cytokine effect size. An effect 
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size was then computed for combined anti-inflammatory chemicals IL-10 and IL-
1ra. Lastly, the effect size for cortisol levels was computed.  
Test of Homogeneity 
 A test of homogeneity is an indicator of the extent to which each 
individual effect size is an estimate of the same population effect. This test is 
represented by the variable Q. In a sample yielding a homogenous effect size, Q 
is non-significant (p>.05) signifying that the individual effect sizes within the 
overall mean effect size only differ with respect to sampling error. For samples in 
which Q is significant (p<.05) the individual effect sizes are said to be 
heterogeneous implying that individual effect size differences do not result from 
only sampling error. In this case, other moderators must be considered in further 
analysis as potential sources which could account for the heterogeneity of the 
individual effect sizes (Hedges, 1982; Lipsey & Wilson 2001) 
 In samples in which the number of individual effect sizes is small, the 
statistical power of Q is reduced resulting in the possibility that the test of 
homogeneity may fail to indicate a heterogeneous sample when a 
heterogeneous sample is present. For this reason, we have also included values 
for the I2 index to complement the Q statistic results. The I2 statistic not only 
indicates whether or not heterogeneity is present but also provides information 
about the extent to which individual effect sizes are heterogeneous. By 
convention, the values of I2=0 (0%), I2=25 (25%), I2=50 (50%), and I2=75 (75%) 
indicate homogeneity, low heterogeneity, medium heterogeneity, and high 
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heterogeneity respectively (Huedo-Medina, Sanchez-Meca, & Marin-Martinez, 
2006). If heterogeneity was indicated based on a significant Q-value, each 
individual study included in the effect size calculation was examined for potential 
moderators. The identified potential moderators were then discussed as 
variables to be considered for future research in this area  
Meta-Analytic Model 
 Multiple meta-analytic models can be utilized in the completion of a 
meta-analysis: fixed-effects, random-effects or mixed-effects. The fixed-effects 
model is used when the source of heterogeneity between studies included in the 
analysis is believed to have come from the study level and effect level coding 
characteristics. A random-effects model is appropriate when variance between 
studies is ascribed to sources of variability that are assumed to be randomly 
distributed beyond random sampling error. Lastly, when the variance between 
studies beyond that which can be attributed to sampling error is thought to be 
primarily systematic but an additional random component of effect size 
distribution is still present, a mixed-effects model should be employed (Lipsey & 
Wilson, 2001). Due to the presence of heterogeneity in the present analysis that 
was not systematic, the random-effects model was utilized. 
Results 
 A summary of all numerical values for individual statistics is provided in 
Table 2. 
Major Adverse Cardiac Events Analysis 
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 There were five studies included in the analysis with MACE as endpoints. 
This yielded five individual effect sizes from a total of 2,066 cardiac patients 
(Type-D=584, non Type-D= 1,482). All studies utilized a longitudinal design, 
included either Denollet or Pederson as researchers and had a patient sample 
that was more than 50% male in composition. Three studies took place in 
Belgium with patients from the Antewerp Cardiac Rehabilitation Program 
whereas the remaining two studies were conducted in the Netherlands. Four of 
the five studies reported 20-29% prevalence of Type-D personality whereas one 
study reported Type-D prevalence between 30-39%. One study reported the 
Type-D sample as being more likely to smoke than the non Type-D sample 
whereas no other significant differences in baseline characteristics between the 
two groups were reported.  All studies were rated at 100% confidence as all 
necessary data for effect size calculation was provided, and no estimation was 
needed. 
 The test of homogeneity produced a non-significant Q=3.27 indicating 
homogenous individual effect sizes. This was further verified by an I2 value of 0%. 
Type-D personality was associated with a higher occurrence of MACE (OR=3.42, 
95% CI=2.48-4.73, p<.001). These results demonstrate that individuals with Type-
D personality have more than three times greater odds of suffering a myocardial 
infarction, percutaneous coronary intervention, coronary artery bypass grafting 
surgery or cardiac death following the diagnosis of heart disease than those 
without Type-D personality. 
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Quality of Life Analysis 
 A total of five studies were included in the quality of life analysis. Two of 
these studies were included in the computation of a single effect size as data 
were presented dichotomously with a total sample size of 521 patients (Type-
D=188, non Type-D=333). The remaining three studies were included in an 
additional computation of effect size as continuous data were provided with a 
total sample size of 368 patients (Type-D=98, non Type-D=270). Three studies 
were completed in the Netherlands, two in Sweden and one in the UK.  Three of 
the five studies included either Denollet or Pederson as researchers. Two studies 
were longitudinal whereas the remaining three were cross sectional. One study 
reported that, at baseline, Type-D patients were more likely to have diabetes 
and have a lower level of education than non-Type-D patients. No other 
differences in baseline characteristics were reported. In all studies, greater than 
50% of the sample was male and mean ages were within the range of 50-69 
years. Two studies reported the prevalence of Type-D personality to be 20-29%, 
two reported the prevalence to be 30-39%, whereas one study had an 
abnormally high prevalence of Type-D personality within the range of 40-49%. 
The data from four of the studies was rated at 100% confidence. One study 
required slight estimation of means and standard deviations from a figure 
presented graphically and, therefore, confidence was rated as 3.5 out of 5. 
 Analysis of the quality of life studies presenting data dichotomously 
produced a significant effect size (OR=3.48, CI= 2.37-5.11, p<.001) as well as 
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homogeneity between studies (Q=.21, p=.65, I2=0) indicating that individuals 
with Type-D personality have more than three times greater odds of 
experiencing a poor quality of life when diagnosed with heart disease than non-
Type-D individuals. In the analyses which included the three studies with 
continuous data, the test of homogeneity resulted in a significant Q value of 
51.88 (p<.001) and an I2 value of 96.15% indicating the presence of 
heterogeneity beyond sampling error alone. The effect size for the relationship 
between the presence of Type-D personality and poor quality of life was found 
to be significant (d=-1.23, p=.01).  
 Potential sources of moderators between individual studies as sources of 
heterogeneity in the data were identified. Aquarius (2007) had an increased 
proportion of smokers and small sample size. Karlsson (2007) differed with 
respect to investigators and a very general and simplistic measure of quality of 
life versus the detailed MLWHFQ and WHOQOL-BREF utilized in the other 
studies. Specific cardiac diagnosis and quality of life measurement differed 
among all three studies.  
 Before these results are discussed further, a narrative review of the 
results of the four excluded quality of life studies is warranted. The first of the 
four excluded studies was conducted at Tweesteden Teaching Hospital in Tilburg, 
Netherlands on 166 patients being treated for chronic heart failure. The patients’ 
disease-specific quality of life was assessed using the MLWHFQ and general 
health status was assessed with the SF-36 at baseline and a one year follow-up. 
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Though there was an overall improvement in general health status over time, 
Type-D’s reported poorer disease-specific as well as general physical and mental 
health status at both time points. Type-D was an independent predictor of poor 
disease-specific mental health status, social functioning, role emotional 
functioning, general health and increased bodily pain following multivariate 
analysis (Schiffer et al., 2008). The second excluded study, also in Tilburg, 
Netherlands at St. Elisabeth Hospital, examined the relationship of Type-D 
personality with quality of life and stress in 150 peripheral artery disease 
patients.  Quality of life was measured with the WHOQOL-100 and the Perceived 
Stress Scale-10. Type-D personality was equally present in patients with mild, 
moderate and severe levels of disease though Type-D patients reported poorer 
quality of life and more perceived stress than non Type-D patients. After 
adjustments for disease status, age and gender, Type-D personality remained 
significantly associated with an impaired quality of life (Aquarius, Denollet, 
Hamming, & De Vries, 2005). The third excluded study was conducted with 186 
surviving heart transplant recipients transplanted at the Erasmus Medical Center 
in Rotterdam, Netherlands between 1985 and early 2003. Perceived health 
related quality of life was assessed with the SF-36. Type-D transplant recipients 
reported poorer quality of life than non Type-D patients on all aspects of the SF-
36, excluding bodily pain. Type-D personality was an independent predictor of 
poor outcome on all dimensions of the SF-36 except bodily pain and general 
health. Of interest, the 18% prevalence of Type-D personality in this study was 
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abnormally low in comparison to other samples. It is hypothesized that this could 
be due to the greater mortality rates of Type-D patients as evidenced in other 
studies as well as this meta-analysis, or the socially inhibited manner in which 
Type-D patients tend to present themselves resulting in a possible decreased 
patient advocacy and reduced placement of Type-D patients on the heart 
transplant list (Pederson et al., 2006). The final excluded study assessed the 
relation between Type-D personality and health related quality of life at baseline 
and three months in 154 implantable cardioverter defibrillator implantation 
patients. Quality of life was measured by the SF-36. Though general 
improvement was observed with time, Type-D patients consistently reported 
poorer quality of life than non Type-D patients (Pederson, Thomas, Muskens-
Heemskerk, Erdman, & Jordaens, 2007).  
Biochemical Markers Analysis 
 There were a total of four studies with endpoints of biochemical markers 
of disease. All analysis conducted with pro-inflammatory cytokines was 
conducted from the data of 305 patients (Type-D=105, non Type-D=200) 
whereas anti-inflammatory cytokine analysis encompassed 84 patients (Type-
D=32, non Type-D=52) and cortisol analysis included 66 patients (Type-D=23, non 
Type-D=43). Two studies were conducted in Belgium, one in England and one in 
the Netherlands. Three of the four studies included either Denollet or Pederson 
as researchers.  Three studies were cross-sectional in design whereas one was 
longitudinal. Two studies found Type-D patients more likely to be NYHA Class 
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III/IV at baseline, one study reported that Type-D patients were more likely to be 
older, and one study reported Type-D patients as more likely to be taking 
diuretics. No other significant differences at baseline were reported. All studies 
consisted of samples with more than 50% males and a 30-39% prevalence of 
Type-D personality. All studies were rated at 100% confidence as all data 
necessary for calculating effect sizes was provided and no estimation was 
needed. 
 The levels of inflammatory cytokine IL-6 were found to be elevated in 
patients with Type-D personality (d=-.26, p=.03) and the test of homogeneity 
indicated homogenous individual effect sizes (Q=.04, p=.98, I2=0%).  The analysis 
of elevated inflammatory cytokine TNF-α and its soluble receptor levels (d=-1.58, 
p=.07) and combination analysis of elevated IL-6, TNF-α, sTNFR-1, and sTNFR-2 
levels (d=-1.10, p=.07) in Type-D versus non Type-D individuals both trended 
towards significance. Both TNF-α, sTNFR-1, and sTNFR-2 combined analysis 
(Q=76.30, p<.001, I2=97.39%) and the combined IL-6, TNF-α, sTNFR-1, and 
sTNFR-2 (Q=48.37, p<.001, I2=95.87%) analysis were also found to be 
heterogeneous indicating that the variance among individual effect sizes cannot 
be explained by mere sampling error. The effect size for TNF-α excluding the 
effects of sTNFR-1 and sTNFR-2 was found to be insignificant (d=-1.07, p=.17) as 
well as heterogeneous (Q=67.07, p<.001, I2=97.02%). Significance was found for 
the effects of sTNFR-1 and sTNFR-2 alone (d=-1.82, p=.05), however, 
heterogeneity was present (Q=81.97, p<.001, I2=97.56%). In analysis of anti-
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inflammatory chemicals IL-10 and IL-1ra (d=-.42, p=.06) the results also trended 
towards significance with Type-D individuals having lower levels of anti-
inflammatory cytokines. The last biochemical analysis of the association between 
Type-D and cortisol levels did not produce significant results (d=-.24, p=.35).  
All heterogeneous studies were examined for the presence of potential 
moderators. Denollet (2009) was identified as a possible source of variance due 
to a greater proportion of the sample being classified as NYHA Class III/IV, a 
greater mean sample age, the presence of kidney dysfunction in fourteen of the 
Type-D patients and a longitudinal study design whereas the other studies were 
cross-sectional.  
 
Discussion 
 Results from the MACE analysis demonstrate a large effect size indicating 
the association of Type-D personality with odds of experiencing a myocardial 
infarction, cardiac mortality, coronary artery bypass grafting surgery and 
percutaneous coronary intervention that are more than three times greater than 
in non Type-D individuals. When quality of life data were presented 
dichotomously, indicating only whether quality of life was impaired or not, the 
results indicated that Type-D patients had more than three times greater odds of 
being classified as having a poor quality of life than those without Type-D 
personality. When data were presented continuously, indicating the severity 
with which quality of life was impaired, in the form of numerical scores on the 
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various quality of life assessments, the effect size was also found to be 
significant.  The consistent results of the four previously summarized excluded 
studies which assess quality of life in heart disease patient groups using similar 
and psychometrically accepted instruments also support the presence of a 
relationship between Type-D personality and poor health-related quality of life. 
The increased sample size would also have increased the statistical precision and 
perhaps have provided a more homogenous outcome. 
 The test of homogeneity with respect to the continuous data quality of 
life analysis implies the presence of moderators in the studies contributing to 
heterogeneity beyond that solely from sampling error. One of these possible 
moderators is the variety of quality of life measures used in the studies.  Three 
different quality of life measures were used in the analysis, and though they all 
have a common objective of measuring quality of life, each differed with respect 
to the others. The SF-36 and Cantril Ladder of Life both measure general quality 
of life whereas the MLWHFQ is disease specific. The Cantril Ladder of Life is a 
very general single measure of the discrepancy between the patients’ real versus 
ideal life whereas the SF-36 and MLWHFQ results are based on a combination of 
scores on multiple detailed dimensions of quality of life. Though all studies used 
cardiovascular disease patient populations, each of three studies included 
patients with differing diagnoses. The three patient populations were either 
diagnosed with acute myocardial infarction or peripheral artery disease, 
underwent coronary artery bypass grafting surgery, or were generally referred to 
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cardiac rehabilitation with no specific diagnosis provided. This raises the 
possibility that differing diagnoses, though all falling under the umbrella of 
cardiovascular disease, may be associated with the variation between effect 
sizes. Additionally, one study took place over a twelve week period with quality 
of life measurements taken at both baseline and twelve weeks. However, the 
patient sample underwent cardiac rehabilitation between quality of life 
measures so only baseline data were utilized in the effect size calculation in 
order to reduce variability between studies. One study was prospective in nature 
but only provided quality of life scores using the Cantril Ladder of Life at baseline 
whereas the other study was also prospective in nature but only provided raw, 
unadjusted data usable in the present meta-analysis for baseline WHOQOL 
scores. If all of these studies had had usable test-retest data, it is possible that 
the quality of life scores may have presented a more precise picture of the 
patients’ quality of life as well as less heterogeneity between the effect sizes. 
These are important variables consider for future research in this area as well as 
any future meta-analysis conducted when a larger sample size is available.
 Of the biochemical markers, the inflammatory cytokines IL-6, sTNFR-1 
and sTNFR-2 were most prominently associated with Type-D personality. Type-D 
patients displayed significantly higher levels of these cytokines compared to non 
Type-D patients. Though the elevated levels of TNF-α in Type-D patients did not 
reach significance, when the TNF-α and its soluble receptor levels were 
combined the results trended towards significance. This pattern may be due to 
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the fact that the majority of TNF-α is found on cell surfaces and has a stimulatory 
effect triggering the release of sTNFR-1 and sTNFR-2 into plasma. Therefore, 
sTNFR-1 and sTNFR-2 are strong indicators of sustained elevated levels of TNF-α 
and are regarded as more accurate predictors of adverse outcome in heart 
disease, primarily chronic heart failure (von Haehling, Jankowska, & Anker, 
2004). Additionally, it has been indicated that the plasma complex formed by 
circulating TNF-α and its soluble receptors stabilizes TNF-α and enhances as well 
as prolongs its pro-inflammatory effects in the body (Aderka, Engelmann, Maor, 
Brakebush, & Wallach, 1992). The combined effect of elevated TNF-α, sTNFR-1, 
sTNFR-2, and IL-6 levels in Type-D versus non Type-D patients also trended 
towards significance. There was, however, a relatively small sample size for each 
analysis resulting in the possibility that an increased sample size may have 
caused the effect sizes that strongly trended towards significance to become 
significant.  
The individual effect sizes from which the overall effect size was 
determined for these non significant analyses as well as the sTNFR-1 and sTNFR-
2 analysis were found to be heterogeneous indicating the presence of possible 
moderators causing variance to be greater than that which can be explained by 
sampling error alone. The studies varied slightly with respect to mean patient 
ages of 57, 59.1 and 65.7 years. The study in which the mean patient age was 
highest also had the highest levels of pro-inflammatory cytokines. TNF-α levels 
have been positively correlated with advancing age (Deswal et al., 2001). The 
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same study also included 14 Type-D patients with kidney dysfunction which is 
also associated with increased pro-inflammatory cytokine levels (Knight et al., 
2004; Pecoits-Filho et al., 2003). This may explain a portion of the between study 
variability and in future research clinical variables that have independent 
associations with biochemical marker levels should be considered. It should also 
be noted that all data used in the present meta-analysis were raw data 
unadjusted for clinical variables such as age, gender, and disease severity. 
Anti-inflammatory cytokine analysis presented a trend towards 
significantly lower levels in Type-D versus non Type-D patients. Cortisol levels did 
not differ between Type-D and non Type-D individuals. This may have been 
affected by the measurement of awakening cortisol levels as well as cortisol 
awakening response in a hospital setting where sleep patterns are interrupted by 
ambient light and noises throughout the night. A study by Molloy and colleagues 
(2008) measured cortisol awakening response as well as cortisol levels 
throughout the day in a non-hospital setting using a patient sample overlapping 
with that of our analysis. They also found no statistically significant difference 
between Type-D and non Type-D patients with respect to the cortisol awakening 
response. They did, however, find elevated levels of cortisol output throughout 
the day in Type-D versus non Type-D individuals. A study using monozygotic and 
dizygotic twin pairs found that chronic stress as well as genetics have a 
substantial influence on cortisol levels after awakening but do not influence the 
cortisol profile over the course of the day (Wust, Wolf, Federenko, Hellhammer, 
35 
 
& Kirschbaum,2000). This is an area that may warrant further study, as there has 
been much focus on the magnitude of the cortisol awakening response in 
connection to disease. 
Cardiac rehabilitation, particularly rehabilitation with a focus on relieving 
emotional distress through group and individual interventions, has been shown 
to reduce mortality in coronary heart disease patients (Denollet & Brutsaert, 
2001). It also may decrease the level of impairment associated with Type-D 
personality and may facilitate improvement in DS-14 scores to a more favorable 
level (Binder, Kohls, Schmid, & Saner, 2007). In contrast, other studies have 
observed improvements in the quality of life of Type-D patients following cardiac 
rehabilitation without improvements in DS-14 scores (Karlsson et al., 2007). 
There are a broad range of options available to alleviate the distress caused by 
Type-D personality such as pharmacological intervention with anti-depressants 
to increase social confidence and reduce the intensity of negative emotions, 
psychotherapy to teach social skills and provide emotional support, cognitive 
behavioral therapy or exercise (Sher, 2005).  However, further research is 
needed to determine whether any of these options to alleviate chronic stress as 
well as emotional distress have any effect in Type-D individuals. 
There are limitations to the present meta-analysis that should be noted. 
These studies were conducted by a moderately concentrated group of 
investigators and were restricted demographically to encompass patients from a 
small number of countries in Europe. There is a need for additional research that 
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encompasses a broader demographic to replicate the previous findings 
concerning Type-D personality and adverse cardiac prognosis. Effect sizes, 
particularly those concerning quality of life and biochemical markers, were 
computed from small sample sizes, many of which were heterogeneous, which 
enforces the need for a broader body of research on the topic. The abundance of 
trends towards significance despite small effect sizes still strongly suggests an 
association between Type-D personality and poor cardiac prognosis.   
These findings converge to strongly suggest that Type-D personality is a 
predictor of poor prognosis following a diagnosis of cardiovascular disease which 
may possibly be explained by disease pathways involving pro- and anti-
inflammatory cytokines. This supports the need for a brief and simple screening 
of cardiovascular patients for Type-D personality in order to provide 
supplemental treatment to this high risk patient population. 
 
 
43 
 
Appendix A 
 
SF-36(tm) Health Survey 
 
Instructions for completing the questionnaire: Please answer every 
question. Some questions may look like others, but each one is different. 
Please take the time to read and answer each question carefully by filling 
in the bubble that best represents your response. 
 
Patient Name: __________________ 
SSN#: ________________________________________ Date:_______ 
Person helping to complete this form: 
___________________________________________________________
_____ 
 
1. In general, would you say your health is: 
 Excellent 
 Very good 
 Good 
 Fair 
 Poor 
 
2. Compared to one year ago, how would you rate your health in general 
now? 
 Much better now than a year ago 
 Somewhat better now than a year ago 
 About the same as one year ago 
 Somewhat worse now than one year ago 
 Much worse now than one year ago 
 
3. The following items are about activities you might do during a typical 
day. Does your health now limit you in these activities? If so, how much? 
a. Vigorous activities, such as running, lifting heavy objects, participating 
in strenuous sports. 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
b. Moderate activities, such as moving a table, pushing a vacuum cleaner, 
bowling, or playing golf? 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
c. Lifting or carrying groceries. 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
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d. Climbing several flights of stairs. 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
e. Climbing one flight of stairs. 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
f. Bending, kneeling or stooping. 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
g. Walking more than one mile. 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
h. Walking several blocks. 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
i. Walking one block. 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
j. Bathing or dressing yourself. 
 Yes, limited a lot. 
 Yes, limited a little. 
 No, not limited at all. 
 
4. During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities as a result of your physical 
health? 
a. Cut down the amount of time you spent on work or other activities? 
 Yes  No 
b. Accomplished less than you would like? 
 Yes  No 
c. Were limited in the kind of work or other activities 
 Yes  No 
d. Had difficulty performing the work or other activities (for example, it took 
extra time) 
 Yes  No 
 
5. During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
a. Cut down the amount of time you spent on work or other activities? 
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 Yes  No 
b. Accomplished less than you would like 
 Yes  No 
c. Didn't do work or other activities as carefully as usual 
 Yes  No 
 
6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbors, or groups? 
 Not at all 
 Slightly 
 Moderately 
 Quite a bit 
 Extremely 
 
7. How much bodily pain have you had during the past 4 weeks? 
 Not at all 
 Slightly 
 Moderately 
 Quite a bit 
 Extremely 
 
8. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and 
housework)? 
 Not at all 
 Slightly 
 Moderately 
 Quite a bit 
 Extremely 
 
9. These questions are about how you feel and how things have been with 
you during the past 4 weeks. For each question, please give the one 
answer that comes closest to the way you have been feeling. How much 
of the time during the past 4 weeks. 
a. did you feel full of pep? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
b. have you been a very nervous person? 
 All of the time 
 Most of the time 
 A good bit of the time 
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 Some of the time 
 A little of the time 
 None of the time 
c. have you felt so down in the dumps nothing could cheer you up? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
d. have you felt calm and peaceful? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
e. did you have a lot of energy? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
f. have you felt downhearted and blue? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
g. did you feel worn out? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
h. have you been a happy person? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
i. did you feel tired? 
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 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 None of the time 
 
10. During the past 4 weeks, how much of the time has your physical 
health or emotional problems interfered with your social activities (like 
visiting friends, relatives, etc.)? 
 All of the time 
 Most of the time 
 Some of the time 
 A little of the time 
 None of the time 
 
11. How TRUE or FALSE is each of the following statements for you? 
a. I seem to get sick a little easier than other people 
 Definitely true 
 Mostly true 
 Don't know 
 Mostly false 
 Definitely false 
b. I am as healthy as anybody I know 
 Definitely true 
 Mostly true 
 Don't know 
 Mostly false 
 Definitely false 
c. I expect my health to get worse 
 Definitely true 
 Mostly true 
 Don't know 
 Mostly false 
 Definitely false 
d. My health is excellent 
 Definitely true 
 Mostly true 
 Don't know 
 Mostly false 
 Definitely false 
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Appendix B 
 
MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE 
 
The following questions ask how much your heart failure (heart condition) 
affected your life during the past month (4 weeks).  After each question, 
circle the 0, 1, 2, 3, 4 or 5 to show how much your life was affected.  If a 
question does not apply to you, circle the 0 after that question. 
 
Did your heart failure prevent you  
from living as you wanted during                        Very                             
the past month (4 weeks) by -                          No      Little                  
       
1.  causing swelling in your ankles or legs?           0      1      2      3      4      5 
2.  making you sit or lie down to rest during    
     the day?                   0       1      2      3      4      5 
3.  making your walking about or climbing      
     stairs difficult?                  0       1      2      3      4      5 
4.  making your working around the house    
     or yard difficult?                   0      1      2      3      4      5 
5.  making your going places away from           
     home difficult?                   0      1      2      3      4      5 
6.  making your sleeping well at night 
     difficult?                    0      1      2      3      4      5 
7.  making your relating to or doing things 
     with your friends or family difficult?                0      1      2      3      4      5 
8.  making your working to earn a living 
     difficult?                    0      1      2      3      4      5                                                               
9.  making your recreational pastimes, sports 
     or hobbies difficult?                  0      1      2      3      4      5 
 
10.  making your sexual activities difficult?    0      1      2      3      4      5 
11.  making you eat less of the foods you  
        like?                    0      1      2      3      4      5 
 
12.  making you short of breath?                 0      1      2      3      4      5 
13.  making you tired, fatigued, or low on 
       energy?                    0      1      2      3      4      5 
 
14.  making you stay in a hospital?     0      1      2      3      4      5 
 
15.  costing you money for medical care?    0      1      2      3      4      5 
 
16.  giving you side effects from treatments?    0      1      2      3      4      5 
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17.  making you feel you are a burden to your  
     family or friends?          0      1      2      3      4      5 
18.  making you feel a loss of self-control 
        in your life?                   0      1      2      3      4      5  
 
19.  making you worry?                  0      1      2      3      4      5 
20.  making it difficult for you to concentrate 
        or remember things?                  0      1      2      3      4      5  
 
21.  making you feel depressed?                 0      1      2      3      4      5 
__________________________________________________________________
_______ 
 
©1986 Regents of the University of Minnesota, All rights reserved.  Do not copy or reproduce 
without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents 
of the University of Minnesota. 
11/10/04 
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Appendix C 
 
 
Cantril Ladder of Life 
 
All of us want certain things out of life. When you think about what really matters in your 
own life, what are your wishes and hopes for the future? In other words, if you image 
you own future in the best possible light, what would you life look like then, if you are to 
be happy? Take your time thinking about 
this. 
 
Now taking the other side to the picture, what are your fears and worries about the 
future? In other words, if you image your future in the worst possible light, what would 
your life look like then? Here is a picture of a ladder. The top of the ladder represents 
the best possible life and the bottom the worst for you. Where on the ladder do you feel 
you personally stand at the present time? 
 
10 BEST POSSIBLE LIFE 
9_________________                                       
8_________________ 
7_________________ 
6_________________ 
5_________________ 
4__________________ 
3_________________ 
2_________________ 
1_________________ 
0 WORST POSSIBLE LIFE 
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Appendix D 
 
Health Complaints Scale 
 
Name:_________________________  Sex:________  Age:_____  
Date:__________ 
 
Below are a number of problems and complaints that ill people often have. 
Please read each item carefully and then circle the appropriate number next to 
that problem. Indicate how much each problem has bothered you lately. Please 
use the following scale to record your answers. 
 
0 NOT AL ALL    1 A LITTLE BIT     2 MODERATELY    3 QUITE A BIT   4 
EXTREMELY 
 
Lately, how much were you bothered by the following specific problems: 
 
A1Sleep that is restless or disturbed         
 0  1  2  3  4 
 
A2Tightness of the chest         
 0  1  2  3  4 
 
A3Feeling that you are not rested        
 0  1  2  3  4 
 
A4Fatigue           
 0  1  2  3  4 
 
A5Trouble falling asleep         
 0  1  2  3  4 
 
A6Inability to take a deep breath        
 0  1  2  3  4 
 
A7Stabbing pain in heart or chest        
 0  1  2  3  4 
 
A8Feeling exhausted without any reason       
 0  1  2  3  4 
 
A9Shortness of breath          
 0  1  2  3  4 
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A10Pain in heart or chest         
 0  1  2  3  4 
 
A11Feeling weak          
 0  1  2  3  4 
 
A12Feeling you can’t sleep         
 0  1  2  3  4 
 
 
Lately, how much have you been bothered by the following problems: 
 
B1The idea that your bad health is the biggest problem in your life    
 0  1  2  3  4 
 
B2Not being able to work fluently, also with hobbies      
 0  1  2  3  4 
 
B3Being afraid of illness         
 0  1  2  3  4 
 
B4The idea that you were able to take on much more work formerly   
 0  1  2  3  4 
 
B5Feeling blocked in getting things done       
 0  1  2  3  4 
 
B6The idea that you have a serious illness       
 0  1  2  3  4 
 
B7Feeling you are not able to do much       
 0  1  2  3  4 
 
B8The idea that something serious is wrong with your body     
 0  1  2  3  4 
 
B9Feeling you are no longer worth as much as you used to be    
 0  1  2  3  4 
 
B10Feeling despondent         
 0  1  2  3  4 
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B11worrying about your health        
 0  1  2  3  4 
 
B12Thinking that all your worries would be over in you were physically healthy  
 0  1  2  3  4 
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Appendix F 
 
STUDY-LEVEL CODING MANUAL 
 
Source Descriptors: 
 
1. Study ID Number (In bold at beginning of reference) 
 
2. Publication Year (Last two digits) 
 
3. Does the study include either Denollet, J or Pederson SS in its list of 
authors? 
 1. Yes     2. No 
 
Sample Descriptors: 
 
4. What is the source of the sample? Specify by the hospital or program from 
which they were selected. 
1. Antewerp Cardiac Rehabilitation Program/University Hospital of   
 Antewerp 
 2. Rotterdam Cardiology Hospital/Organization for Cardiac Rehabilitation 
 3. Harefield Hospital 
 4. TweeSteden Teaching Hospital 
 5. St. Elisabeth Hospital 
 6. London Hospitals 
 7. Danderyd Hospital 
 8. Erasmus Medical Center 
 9. General Practice 
 
5. What is the specific cardiac diagnosis or necessary treatment/procedure of 
the patients which qualified them for the study? Select multiple diagnoses if 
the sample included more than one cardiac pathology or procedure. 
1. Myocardial Infarction   
2. Coronary Artery Bypass Grafting Surgery (CABG) 
 3. Angioplasty /Percutaneous Coronary Intervention (PCI) 
 4. Referred to/Participating in Cardiac Rehabilitation Program 
 5. Chronic/Congestive Heart Failure (CHF), specify if systolic/diastolic  
  noted 
 6. Peripheral Artery Disease (PAD) 
 7. Coronary Heart Disease (CHD) 
 8. Acute Coronary Syndrome (ACS) 
 9. Heart Transplant 
 10. Implantable Cardioverter Defibrillator (ICD) Implantation 
 
6. Predominant gender of sample. Select the code for the correct proportion 
of men in the sample. 
 1. <5% male    2. 5-50% male 
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 3. 50% male    4. 50-95% male 
 5. >95% male    6. Information not reported 
 
7.  Mean age of sample. Select correct age bracket or indicate that it is 
stratified by percent greater than a specific age. 
 1. 20-49 years old   2. 50-59 years old 
 3. 60-69 years old   4. 70-79 years old 
 5. 80 years or older   6. Information reported as % of  
7. Information not reported                 sample greater than a specified age  
(please specify the age) 
       
 
8. Proportion of sample that engages in tobacco use. Select the correct 
percentage bracket. 
 1. 0-24% smokers    2. 25-49% smokers 
 3. 50-74% smokers    4. 75-89% smokers 
 5. 90-100% smokers    6. Information not reported 
 
9. Proportion of sample with impaired Left Ventricular Ejection Fraction 
(LVEF). This has no absolute definition and is defined slightly different from 
study to study. Select based on the proportion that is less than the cut-off 
percentage specified in the study. For example, one study may specify the 
proportion of patients with an LVEF <50% while another specified the 
proportion with an LVEF <40%, code for the proportion defined as 
impaired according to the specific study. Only a mean LVEF is provided 
specify and provide the mean. 
 1. 0-24% impaired LVEF   2. 25-49% impaired LVEF 
 3. 50-74% impaired LVEF   4. 75-89% impaired LVEF 
 5. 90-100% impaired LVEF   6. Information not reported 
 7. Only mean LVEF reported (specify) 
 
10. Proportion of sample with 
hyperlipidemia/hypercholesterolemia/dyslipidemia.  Select the correct 
percentage bracket. 
 1. 0-24% high cholesterol   2. 25-49% high cholesterol 
 3. 50-74% high cholesterol   4. 75-89% high cholesterol 
 5. 90-100% high cholesterol   6. Information not reported 
 
11. Proportion of sample with hypertension. Select the correct percentage 
bracket. 
 1. 0-24% hypertension   2. 25-49% hypertension 
 3. 50-74% hypertension   4. 75-89% hypertension 
 5. 90-100% hypertension   6. Information not reported 
 
12. Proportion of sample with diabetes. Select the correct percentage 
bracket. 
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 1. 0-24% diabetes    2. 25-49% diabetes 
 3. 50-74% diabetes    4. 75-89% diabetes 
 5. 90-100% diabetes    6. Information not reported 
 
13. Proportion of sample with renal impairment. Select the correct 
percentage bracket. 
 1. 0-24% renal impairment   2. 25-49% renal impairment 
 3. 50-74% renal impairment   4. 75-89% renal impairment 
 5. 90-100% renal impairment   6. Information not reported 
 
14. Proportion of sample classified as NYHA Class III and IV. Select the 
correct percentage bracket.  
 1. 0-24% severe disease   2. 25-49% severe disease 
 3. 50-74% severe disease   4. 75-89% severe disease 
 5. 90-100% severe disease   6. No information reported 
 
15. Proportion of the sample classified as Type-D Personality. Select the 
correct percentage bracket. 
 1. 0-9% Type-D    2. 10-19% Type-D 
 3. 20-29% Type-D    4. 30-39% Type-D 
 5. 40-49% Type-D    6. 50-59% Type-D 
 7. 60-69% Type-D    8. 70-79% Type-D 
 9. 80-89% Type-D    10. 90-100% Type-D 
 11. Information not provided 
 
16. Are the baseline characteristics of the Type-D’s vs. non Type-D’s 
significantly different? 
 1. Yes (specify which aspects are significantly different) 
 2. No 
 3. Information not provided 
 
Research Design Descriptors: 
 
17. How were the patients selected? Choose best possible selection. 
 1. A consecutive series of patients at a particular hospital or rehabilitation  
program were approached and asked to participate in the study  
2. Patients being treated at a particular hospital or rehabilitation program  
were approached and asked to participate in the study, however 
whether they were consecutively selected is not indicated 
 3. Patients were selected from the registry of another larger study/database 
4. Patients were selected based on past treatment received (retrospective  
selection) 
 
18. What was the study design? Choose the best possible selection. 
 1. Longitudinal 
  1a. Prospective 
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  1b. Retrospective     
2. Cross Sectional 
     
19. What was the total sample size of the study? Select the correct bracket. 
 1. <100 patients    2. 100-199 patients 
 3. 200-299 patients    4. 300-399 patients 
 5. 400-499 patients    6. >500 patients 
 
20. What was the measure used to assess Type-D personality?  
 1. DS-14   2. DS-16 
 3. DS-24   4. Measure NA and SI separately and then 
Combined to classify as Type D (please 
specify which measures were used for NA 
and SI) 
 
 
 
EFFECT SIZE LEVEL CODING MANUAL 
 
1. Study ID Number 
 
2. Effect Size Number 
 
Dependent Measure Descriptors:  
 
3. Effect size type. Not sure how this applies because there isn’t really any 
interventions, they all seem to be post-tests but some have multiple post tests 
and some have only one so do we need to code for this and if so what options 
would we use? 
 
4. What was the length of time of the study. For studies in which follow up 
varies, code for the mean time of follow-up. 
 1. 0 weeks     2. 1-4 weeks 
 3. 5-12 weeks     4. 13-24 weeks 
 5. 25-52 weeks    6. 53-156 weeks 
 7. 157-260 weeks    8. >260 weeks 
 
5. What was the outcome construct that was measured? Select all sub-
categories that apply. 
 1. Major Adverse Cardiac Event  
  1a. Cardiac Death   1b. Myocardial Infarction 
  1c. PCI    1d. CABG 
   
2. Quality of Life Measurement 
 2a. Health Complaints Scale   
2b. Global Mood Scale 
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 2c. Short Form Health Survey SF-36     
2d. Minnesota Living with Heart Failure Questionnaire  
 (MLWHFQ) 
2e. World Health Organization Quality of Life Assessment  
 Instrument-100 (WHOQOL) 
2f. Perceived Stress Scale-10 
2g. Cantril Ladder of Life 
 
 3. Body Chemical Levels 
  3a. TNF-alpha    3b. sTNFR-1 and 2 
  3c. IL-6    3d. IL-10 
  3e. IL-1ra    3f. Cortisol 
 
6. What was the type of data the effect size was based on?  
 1. Dichotomous frequencies and proportions 
 2. Means and standard deviations 
 3. Other (specify) 
 
7. Specify the page number on which the effect size data was found 
 
8. Was the outcome better or worse for the Type-D group? This should be 
only based on the numbers and not on the significance reported in the study 
 1. Better  2. Worse  3. No Difference 
 
9. When dichotomous frequencies and proportions are reported: 
 9a. What is the Type-D sample size? 
 9b. What is the non Type-D sample size? 
 9c. How many total events, or what proportion of the group experienced  
an event occurred in the Type-D group? (when death is reported 
the event should only be counted if it is a cardiac death) 
9d. How many total events, or what proportion the group experienced an  
event in the non Type-D group? (when death is reported the event 
should only be counted if it is a cardiac death) 
 
10. When means and standard deviations are reported: 
 10a. What is the Type-D sample size? 
 10b. What is the non Type-D sample size? 
 10c. What was the mean for the Type-D group? 
 10d. What was the mean for the non Type-D group? 
 10e. What was the standard deviation for the Type-D group? 
 10f. What was the standard deviation for the non Type-D group? 
 
11. If a test of significance was completed, was having Type-D personality 
found to be a significant predictor of a worse outcome? (If there is a case 
where there was significance for some measurements but not others select 
“1” and verify which outcomes were significant) 
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1. Yes   2. No   3. Significance testing not  
          done 
 
12. In studies when significance testing was done a second time using 
multivariate logistic regression controlling for other variables/step-
wise/logistic regression/MANCOVA, was having Type-D personality found to 
be a significant predictor of a worse outcome? (If there is a case where there 
was significance for some measurements but not others select “1” and verify 
which outcomes were significant) 
 1. Yes   2. No   3. Multivariate testing not  
           done 
 
13. Report the effect size to two significant figures using a plus sign when 
there is a better outcome for the Type-D’s and a minus sign when there is a 
worse outcome for the Type-D’s. 
 
14. What is the confidence rating in effect size computation? 
1. Highly estimated (have N and crude p-value only, such as p<.1, and  
 must reconstruct via rough t-test equivalence) 
 2. Moderate estimation (have complex but relatively complete statistics,  
  such as multi factor ANOVA, as a basis for estimation) 
 3. Some estimation (have unconventional statistics and must convert to  
equivalent t-values or have conventional statistics but incomplete, 
such as exact p-level) 
 4. Slight estimation (must use significance testing statistics rather than  
descriptive statistics, but have complete statistics of conventional 
sort) 
5. No estimation (have descriptive data such as means, standard  
deviations, frequencies, proportions, etc. and can calculate the 
effect size directly) 
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Appendix G. 
 
Study-Level Coding Form for Type-D Meta-Analysis 
 
Bibliographic Reference: 
Source Descriptors 
 
1. Study ID Number: 
2. Publication Year:  
3. Denollet, J or Pederson SS an author? 
 
Sample Descriptors 
 
4. Source of the sample:  
5. Specific cardiac diagnosis or treatment: 
6. Predominant Gender: 
7. Mean age: 
8. Proportion engaging in tobacco use:  
9. Proportion with impaired LVEF: 
10. Proportion with hyperlipidemia/hypercholesterolemia/dyslipidemia: 
11. Proportion with hypertension: 
12. Proportion with diabetes: 
13. Proportion with renal impairment: 
14. Proportion NYHA Class III or IV: 
15. Proportion with Type-D personality: 
16. Baseline characteristics for Type-D’s and non Type-D’s significantly  
 different? 
 
Research Design Descriptors: 
 
17. How patients were selected: 
18. Study design: 
19. Total sample size: 
20. Measure used to assess Type-D Personality: 
 
 
Effect Size Level Coding Form for Type-D Meta-Analysis 
 
1. Study ID number: 
2. Effect size number: 
 
Dependent Measure Descriptors 
 
3. Effect size type: 
4. Length of time of study: 
5. Outcome construct measured: 
6. Type of data the effect size was based on: 
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7. Page number on which effect size data was found: 
8. Outcome better or worse for Type-D group: 
9a. Type-D sample size: 
9b. Non Type-D sample size: 
9c. n(total events in Type-D group): 
9d. n(total events in non Type-D group): 
10a. Type-D sample size: 
10b: Non Type-D sample size: 
10c. Type-D group mean: 
10d. Non Type-D group mean: 
10e. Type-D group standard deviation: 
10f. Non Type-D group standard deviation: 
11. With significance testing was Type-D a significant predictor of worse  
 outcome? 
12. In controlled significance testing was Type-D a significant predictor of worse  
 outcome?  
13. Effect size to two significant figures with +/- signs: 
14. Confidence rating in effect size computation: 
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Figure 1. 
Exclusion of Studies 
 
 
50 studies relevant to topic 
 
 
 
 
 5 excluded: lacked non type-
D subsample or complete 
type-D analysis 
3 excluded: contained only 
healthy patient samples 
18 excluded: did not contain 
selected outcome measures 
5 excluded: overlapping 
patient populations 
1 excluded: no cardiac 
events 
4 excluded: no standard 
deviations provided 
 
5 studies analyzed for 
MACE 
(n=5) 
 
5 studies analyzed for 
QOL 
(n=5) 
4 studies analyzed for 
biochemical markers 
(n=4) 
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Capstone Project Summary 
 A meta-analysis is a research method which takes all of the studies done on a 
particular research topic and allows researchers to combine the results and to better 
examine the nature of the area of investigation. Results are reported in terms of a 
quantitative measure referred to as an effect size. This allows for an increased sample 
size which means a meta-analysis has greater statistical power than individual studies. A 
large quantity of primary research has been completed to examine whether there is a 
relationship between Type-D personality and negative outcomes for heart disease 
patients, but no meta-analysis has been completed in the area. The cardiovascular 
patient populations that have been studied are those diagnosed with chronic heart 
failure, coronary heart disease, peripheral artery disease or acute coronary syndrome, 
were attending cardiovascular rehabilitation, underwent coronary artery bypass grafting 
surgery or percutaneous coronary intervention (angioplasty), or experienced a 
myocardial infarction (heart attack). It is for that reason I chose to complete a meta-
analysis on this topic for my Capstone Project. 
 A person who exhibits Type-D personality experiences a high level of negative 
emotions such as anger, sadness, and anxiety. In addition, they do not express their 
emotions and are extremely socially reserved for fear of rejection by others. Screening 
for Type-D personality is accomplished by a brief fourteen item psychometrically sound 
self-survey questionnaire called the DS-14. The DS-14 presents statements such as “I am 
often happy”, “I am often in a bad mood”, and “I often find myself worrying about 
something”. Individuals completing the survey rank statements such as these on a scale 
of 0-5 indicating the truth of the statement as it pertains to them. This method of 
identification of Type-D personality has been shown to produce consistent results over 
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time which is important because Type-D is a stable construct that remains constant in 
individuals unlike depression, for example, which changes in severity and can disappear 
as time progresses.  
 The first step of this research was to conduct a literature search using PsycInfo 
and Pubmed as well as a backwards search through references of recent articles on the 
topic, called an ancestral search, in order to obtain all the research that had been 
completed to date on the topic. The most common theme among the articles was the 
examination of whether Type-D personality in cardiovascular patients was associated 
with: 1) higher incidences of major adverse cardiac events (MACE) which were described 
as cardiac death, myocardial infarctions, coronary artery bypass grafting surgery, or 
percutaneous coronary intervention (formerly referred to as an angioplasty), 2) poor 
quality of life, or 3) higher levels of disease promoting pro-inflammatory and lower 
levels of disease preventing anti-inflammatory cytokine levels. Separate analysis was 
conducted for each outcome. 
 A list of criteria was established for the inclusion or exclusion of each study to 
ensure that only studies done in a similar manner and with adequate data would be 
included in the analysis. This reduced the total number of studies to five for the MACE 
analysis, five for the quality of life analysis, and four for the biochemical markers 
analysis. All of the studies were then coded. This involved the development of a coding 
book detailing all of the variables within the study and options to classify each study 
with respect to each of their characteristics. This allows for direct comparison of the 
similarities and differences between the studies and helps identify sources of variation 
between the studies which could affect the results. In order to ensure this was done 
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correctly, each study was coded by both myself and another masters level individual 
trained using the coding manual. 
 Once all of the data were coded, they were passed to Dr. Glen Spielmans who is 
a meta-analytic expert at Metropolitan State University in Minnesota. He calculated 
effect sizes for each individual study and overall effect sizes for all related studies. He 
also conducted significance testing and tests to determine the degree of variability 
between studies. If studies are found to be heterogeneous, meaning there is more 
variability between the individual studies than is due to sampling error alone, 
moderators within the studies need to be identified as possible sources of that 
variation. 
 The results indicated that cardiovascular patients with Type-D personality  had 
more than three times greater odds of experiencing a major adverse cardiac event 
following diagnosis then non Type-D patients. The quality of life analysis was divided 
into two separate effect sizes depending on whether the individual studies reported 
quality of life with dichotomous data (does the patient have a poor quality of life or not) 
or continuous data (to what degree is the patients’ quality of life impaired). The effect 
size using dichotomous data was significant indicating that Type-D patients had more 
than three times greater odds of experiencing an impaired quality of life than non Type-
D patients. The effect size calculated using continuous data came extremely close to 
being significant. The sample size for the calculation was small because four studies had 
to be excluded due to omissions in their reported data. It is hypothesized that had these 
studies been included and the sample size been larger, the relationship between Type-D 
personality and quality of life may have reached significance for the continuous data as 
well. 
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 There were multiple effect sizes calculated in the biochemical markers analysis 
in order to observe the relationship between Type-D personality and levels of individual 
chemicals as well as combinations of chemicals. IL-6 and TNF-α are pro-inflammatory 
cytokines. When pro-inflammatory cytokines are elevated for sustained periods of time 
they have a disease promoting effect. High sustained levels of TNF-α cause the release 
of its soluble receptors, sTNFR-1 and sTNFR-2, into blood plasma. Consequently, these 
are more accurate indicators of sustained elevated TNF-α levels than the presence of 
TNF-α plasma levels alone. Elevated levels of these pro-inflammatory cytokines have 
been demonstrated to predict mortality among cardiovascular patients. The results 
show that Type-D patients are more likely than non Type-D patients to have elevated 
levels of IL-6, sTNFR-1, and sTNFR-2. There were no differences found between the 
patient groups with respect to TNF-α levels. However, when analysis was completed 
using combined levels of TNF-α, sTNFR-1, and sTNFR-2 the elevation of these levels in 
Type-D patients compared to non Type-D patients was nearly found to be significant. 
Combination of the levels of all the pro-inflammatory chemicals was also nearly found 
to be significantly higher in Type-D individuals. 
 IL-10 and IL-1ra are anti-inflammatory cytokines which have inhibitory effects 
on the pro-inflammatory cytokines in order to regulate the inflammatory process and 
prevent the excess inflammation that leads to disease. Significance was not reached, but 
there was a trend towards lower levels of these chemicals in Type-D versus non Type-D 
patients. Cortisol is a chemical with both inflammatory and anti-inflammatory 
properties. Chronically elevated cortisol levels promote disease progression as well as 
abdominal obesity which has been linked to high cholesterol and atherosclerosis. No 
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differences were found among cortisol levels between the Type-D and non Type-D 
patient groups. 
 All of the biochemical marker analyses had small sample sizes as this is a 
relatively new direction of research. Many of the obtained effect sizes bordered on, but 
did not reach, significance. With such small sample sizes this suggests that there may 
still be a relationship between levels of these chemicals and Type-D personality. Further 
research in this area is needed to establish a definite relationship.  
 Variability between studies which was greater than that due to sampling error 
alone was also found in the quality of life analysis using continuous data as well as many 
of the biochemical analysis data. Because of this, differences between the studies that 
could possibly affect the data needed to be considered. Quality of life was assessed with 
a different measurement instrument in each of the quality of life studies that presented 
their data in a continuous form. Though the aim of each of these tools was to assess 
quality of life, they all did so in a different way. One was specific to the effect of chronic 
heart failure on quality of life while the other two could be generalized to all patient 
groups. One was very simple, basically a rating of how your current life compares to you 
ideal life, while the other two assessed extremely detailed dimensions of quality of life 
with specific questions. If the same quality of life measure had been used in all three 
studies it is possible that there would be less variability between the studies. Also, 
though each study used a patient population falling under the umbrella of 
cardiovascular disease, each patient population differed in their specific diagnosis. One 
study used patients generally in cardiac rehabilitation, one used myocardial infarction or 
coronary artery bypass grafting surgery patients and the last used peripheral artery 
disease patients. This could also account for variability between studies. Possible 
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sources for variation between studies in the biochemical marker analysis were 
differences in average patient age and the inclusion of fourteen kidney dysfunction 
patients within the Type-D group in one study. Both advancing age and kidney 
dysfunction have been found to be sources of elevated levels of pro-inflammatory 
cytokines. 
 The findings of this meta-analysis have some important implications. Not only 
was Type-D personality found to be a powerful predictor of major adverse cardiac 
events and poor quality of life in cardiovascular patients, but it is also strongly suggested 
that it has links to disease promoting biochemicals that have been found to predict 
mortality in this patient population. All of the primary research was conducted in a small 
number of countries in Europe, primarily the Netherlands, by a concentrated group of 
researchers. This study urges for a broader body of research to be completed in order to 
draw more definite conclusions and allow for the results to be generalized to a more 
expansive demographic.  
 The study also calls attention to the need for Type-D screening to be completed 
on cardiovascular patients as this is a very high risk patient group, and the prevalence of 
Type-D personality has been found to be about 20-39% in patient samples. It also 
suggests that research be conducted to examine possible treatments to improve the 
prognosis for Type-D individuals. Some suggested treatments are pharmacological with 
anti-depressants to decrease the intensity of negative emotions, exercise, cognitive 
behavioral therapy, social skills training and coping mechanisms. All of these treatments 
aim to decrease emotional distress and increase social support. A definite association 
has been established between Type-D personality and poor prognosis in this meta-
analysis. This research should further call attention to the need for additional and 
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specialized treatment to improve the survival of Type-D patients and, hopefully, in the 
future will result in changes in the clinical environment to facilitate this high-risk patient 
groups’ survival rates. 
  
 
Table 1 
Study Information Chart 
 
Study Sample Type-D Measurement Construct Measured Effect Size 
Denollet et al., 
2000 
 
319 patients at Antewerp 
Cardiac Rehabilitation 
Center eligible if had myocardial infarction, 
coronary artery bypass grafting surgery, or 
percutaneous coronary  
intervention within 2 months 
of entering program 
(Jan. 1989-Dec 1992) 
 
DS-16 
 
MACE: Cardiac Death,  
Myocardial Infarction, Coronary  
Artery Bypass Grafting Surgery,  
Percutaneous Coronary Intervention 
 
OR = 4.14 
 
Pederson et al., 
2004 
 
875 patients treated with percutaneous 
coronary intervention as part of  
 
DS-14 
 
MACE: Cardiac Death,  
Myocardial Infarction 
 
OR = 4.47 
 
 
Schiffer et al., 
2009 
 
232 chronic heart failure outpatients 
 From cardiology unit of 
Tweesteden teaching hospital 
 
DS-14 
 
MACE: Cardiac Death 
 
OR = 2.16 
 
Denollet et al., 
2006 
 
337 chronic heart disease patients 
participating in Antewerp  
Cardiac Rehabilitation Center  
(Jan. 1993-Dec. 1997) 
 
DS-16 
 
MACE: Cardiac Death,  
Myocardial Infarction, Coronary  
Artery Bypass Grafting Surgery, 
Percutaneous Coronary Intervention 
 
OR = 2.88 
 
Denollet et al., 
1996 
 
303 chronic heart disease patients 
participatingin Antewerp  
Cardiac Rehabilitation 
Center (Jan 1985-Dec 1988) 
 
State Trait Anxiety Inventory 
(negative affectivity measure) 
 Social Inhibition Scale of the Heart 
Patients Psychological 
Questionnaire (social inhibition 
measure) 
MACE: Cardiac Death 
 
OR = 4.98 
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Al-Ruzzeh et al., 
2005 
 
437 coronary artery bypass grafting surgery 
patients who came in for annual  
follow-up at Harefield Hospital 
 
DS-14 
 
QOL: SF-36 
 
OR =3.63 
 
Pelle et al., 
2008 
 
368 patients referred to Rotterdam  
Organization for Cardiac Rehabilitation 
 
DS-14 
 
QOL: SF-36 
 
d = -.62 
 
Schiffer et al., 
2005 
 
84 systolic heart failure patients visiting 
heart failure outpatient clinic at Tweesteden 
teaching hospital 
 
DS-14 
 
QOL: Health Complaints Scale, MLWHFQ 
 
OR = 2.86 
 
Karlsson et al., 
2007 
 
224 acute myocardial infarction or  
coronary artery bypass grafting  
surgery patients from Danderyd Hospital 
 
DS-14 
 
QOL: Cantril Ladder of Life 
 
d = -2.2 
 
Aquarius et al., 
2007 
 
150 peripheral artery disease patients 
 from outpatient clinic 
at St. Elisabeth Hospital 
 
DS-14 
 
QOL: WHOQOL 
 
d = -.88 
 
 
Denollet et al., 
2008 
 
130 chronic heart failure patients from 
outpatient heart failure  
clinic at University Hospital of Antewerp 
 
DS-14 
 
Biochemical Markers:  
TNF-α, sTNFR-1,  
sTNFR-2, IL-6 
 
d = -2.70 
 
 
Denollet et al., 
2009 
 
165 chronic heart failure outpatients from 
Tweesteden teaching hospital 
 
DS-14 
 
Biochemical Markers:  
TNF-α, sTNRF-1, sTNFR-2,  
IL-6, IL-10, IL-1ra 
 
d = -.51 
 
Conraads et al., 
2006 
 
91 chronic heart failure patients from 
outpatient clinic of University  
Department of Cardiology 
DS-14 
 
Biochemical Markers: TNF-α, sTNRF-1, 
sTNRF-2, IL-6 
 
d = -.57 
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Whitehead et 
al., 2007 
 
72 acute coronary syndrome patients 
recruited from four London hospitals 
 
DS-16 
 
Biochemical Markers:  
Cortisol 
 
d=-.24 
 
 
*MACE: Major Adverse Cardiac Event 
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Table 2 
Summary of Statistical Data for Individual Analyses 
 
 
Construct k n(Type-D) n(non Type-D OR CI d Z p(ES) Q p(Q) I2 
MACEa 5 584 1482 3.42 2.48-4.73   <.001 3.27 .51 0% 
QOL 
(Dichotomous 
Data) 
2 188 333 3.48 2.37-5.11   <.001 .21 .65 0% 
QOL 
(Continuous 
Data) 
3 98 270   -1.23 2.61 .01 51.88 <.001 96.15% 
IL-6 3 105 200   -.26 2.17 .03 .04 .98 0% 
TNF-α 3 105 200   -1.07 1.38 .17 67.07 <.001 97.02% 
sTNFR-1 + 
sTNFR-2 3 105 200   -1.84 1.97 .05 81.97 <.001 97.56% 
TNF-α, sTNFR-1 
+ sTNFR-2 3 105 200   -1.58 1.80 .07 76.30 <.001 97.39% 
IL-6 , TNF-α, 
sTNFR-1 + 
sTNFR-2 
3 105 200   -1.10 1.84 .07 48.37 <.001 95.87% 
IL-10 + IL-1ra 1 32 52   -.42 1.86 .06    
Cortisol 1 23 43   -.24 .93 .35    
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aMACE- Major Adverse Cardiac Event (Cardiac Death, MI, CABG, or PCI) 
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Table 3 
Summary of Moderator Analysis Data 
 
 
Included Studies Excluded 
Study 
Moderators Tested For d            Z P(ES) Q P(Q) I2 
QOL: Aquarius et al., 
2007 + 
Karlsson et al., 2007 
Pelle et al., 
2008 
Longitudinal design 
Patients underwent cardiac rehabilitation 
-1.54 2.34 .019 26.01 <.001 96.16% 
QOL: Aquarius et al., 
2007 +  
Pelle et al., 2008 
Karlsson et al., 
2007 
Different group of researchers 
Simplistic and generalized QOL 
measurement 
-.50 1.33 .18 12.24 <.001 91.83% 
QOL: Karlsson et al., 
2007 + 
Pelle et al., 2008 
Aquarius et al., 
2007 
Larger proportion of smokers 
Smaller sample size 
-1.16    1.13 .26 87.69 <.001 98.86% 
Pro-inflammatory 
Cytokines: 
Conraads et al., 2006 
+ Denollet et al., 2008 
Denollet et al., 
2009 
Higher proportion of patients NYHA III/IV 
Longitudinal design 
Greater mean age 
Fourteen Type-D patients with kidney 
dysfunction 
-1.63 1.53 .13 37.28 <.001 97.32% 
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